Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Baird Maintains Outperform on Twist Bioscience, Lowers Price Target to $33

Baird Maintains Outperform on Twist Bioscience, Lowers Price Target to $33

Baird analyst Catherine Schulte maintains Twist Bioscience (NASDAQ:TWST) with a Outperform and lowers the price target from $56 to $33.

byBenzinga Newsdesk

November 21, 2022

1 minute read

Baird analyst Catherine Schulte maintains Twist Bioscience (NASDAQ:TWST) with a Outperform and lowers the price target from $56 to $33.

These Two Companies Surpass Nvidia, Apple And Microsoft with Astounding 1000% Returns In 2023

By Benzinga Neuro

December 28, 4:12 AM

The two companies outperformed the 'Magnificent Seven' group of stocks, which includes tech giants such as Nvidia, Apple, and Microsoft.

CVNA

News

‘Tesla Applies For Massive $700 Million Expansion Of Gigafactory Texas’ – Electrek

By Benzinga Newsdesk

January 10, 4:58 PM

https://electrek.co/2023/01/10/tesla-applies-massive-million-expansion-gigafactory-texas/ Tesla has applied with the Texas state department of licensing for a massive $700 million expansion of Gigafactory Texas in

TSLA

Braze Analysts Riase Their Forecasts After Strong Q1 Results

By Lisa Levin

June 9, 10:35 AM

Braze, Inc. (NASDAQ: BRZE) posted upbeat first-quarter results and issued strong forecast.

BRZE

Analyst Ratings

Expert Ratings for Clene

By Benzinga Insights

September 21, 8:01 AM

Clene (NASDAQ:CLNN) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish…

CLNN

Baird Maintains Outperform on Twist Bioscience, Lowers Price Target to $33

Related Posts

These Two Companies Surpass Nvidia, Apple And Microsoft with Astounding 1000% Returns In 2023

‘Tesla Applies For Massive $700 Million Expansion Of Gigafactory Texas’ – Electrek

Braze Analysts Riase Their Forecasts After Strong Q1 Results

Expert Ratings for Clene